JPRN-UMIN000012204已完成2 期
A phase2 study to evaluate the efficacy and safety of weekly nab-paclitaxel in combination with carboplatin in patients with cancer of unknown primary - Efficacy and safety of weekly nab-paclitaxel plus CBDCA in patients with CUP
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Pregnancy or breast feeding. 2)Patients unable to take nab-paclitaxel and CBDCA because of significant cardiovascular abnormalities, renal dysfunctions, hepatic insufficiency, uncontrolled diabetes, uncontrolled hypertension, bleeding tendency, active interstitial pneumonia,etc. 3)Known HIV, active hepatitis B, active hepatitis C, and/or other known severe infections, including but not limited tuberculosis. 4)Ascites, pleural effusion, pericardial effusion, which require regular drainage. 5)Any other active malignancy unless free of disease for at least five years. 6)Known active brain metastasis. 7)Known hypersensitivity to any of platinum drugs, paclitaxel, and albumin containing drugs. 8)Specific clinicopathologic subgroups which have effective management. a)Woman with isolated axillary lymph node metastasis. b)Patients with CUP presenting as metastatic cervical or isolated inguinal lymphadenopathy(squamous cell carcinoma). c)Men with features of the extra gonadal germ cell cancer syndrome. d)Men with features of prostate cancer(adenocarcinoma, elevated level of PSA, and osteoblastic bone metastasis). e)Neuroendcrine tumors.
研究者
相似试验
进行中（未招募）
1 期
A study assessing the efficacy and safety of an investigational drug called fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participantsEUCTR2020-002858-24-SEClementia Pharmaceuticals Inc, an Ipsen Company98
尚未招募
2 期
A Phase 2 study to assess the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participantsNL-OMON54489Ipsen Pharmaceuticals5
招募中
2 期
A study assessing the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for FOPfibrodysplasia ossificans progressivaJPRN-jRCT2041220080egar Karimian4
招募中
1 期
A Phase 2 Study to assess the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participants.Fibrodysplasia Ossificans ProgressivaCTIS2024-511469-13-00Clementia Pharmaceuticals Inc. An Ipsen Company98
进行中（未招募）
1 期
A Phase 2 study to assess the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participantsfibrodysplasia ossificans progressiva (FOP)MedDRA version: 20.0Level: PTClassification code 10068715Term: Fibrodysplasia ossificans progressivaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-002858-24-NLClementia Pharmaceuticals Inc, an Ipsen Company98